Boxes for Wegovy and Zepbound in California, May 8. JoNel Aleccia / Associated Press

New weight-loss drugs are working wonders, but they’re also out of many patients’ financial reach. Enrollees in Medicare, Medicaid and most employer insurance plans generally don’t cover them.

President Trump has changed that by asking companies to negotiate discounts with the government. Novo Nordisk’s list price for Wegovy is $1,349.02 for a four-week supply. Ozempic, also from Novo Nordisk, has a list price of $1,000. But to gain access to the Medicare market, the company has agreed to sell either drug for $245 plus a $50 patient copayment.

Read the original article on the Wall Street Journal.